Details

Autor(en) / Beteiligte

• Spatz, Erica S
• Gottlieb, Michael
• Wisk, Lauren E
• Anderson, Jill
• Chang, Anna Marie
• Gentile, Nicole L
• Hill, Mandy J
• Huebinger, Ryan M
• Idris, Ahamed H
• Kinsman, Jeremiah
• Koo, Katherine
• Li, Shu-Xia
• McDonald, Samuel
• Plumb, Ian D
• Rodriguez, Robert M
• Saydah, Sharon
• Slovis, Benjamin
• Stephens, Kari A
• Unger, Elizabeth R
• Wang, Ralph C
• Yu, Huihui
• Hota, Bala
• Elmore, Joann G
• Weinstein, Robert A
• Venkatesh, Arjun

Titel

Three-Month Symptom Profiles Among Symptomatic Adults With Positive and Negative Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Prospective Cohort Study From the INSPIRE Group

Ist Teil von

• Clinical infectious diseases, 2023-05, Vol.76 (9), p.1559-1566

Ort / Verlag

US: Oxford University Press

Erscheinungsjahr

2023

Quelle

Oxford Journals 2020 Medicine

Beschreibungen/Notizen

• Abstract Background Long-term symptoms following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection are a major concern, yet their prevalence is poorly understood. Methods We conducted a prospective cohort study comparing adults with SARS-CoV-2 infection (coronavirus disease-positive [COVID+]) with adults who tested negative (COVID−), enrolled within 28 days of a Food and Drug Administration (FDA)-approved SARS-CoV-2 test result for active symptoms. Sociodemographic characteristics, symptoms of SARS-CoV-2 infection (assessed with the Centers for Disease Control and Prevention [CDC] Person Under Investigation Symptom List), and symptoms of post-infectious syndromes (ie, fatigue, sleep quality, muscle/joint pains, unrefreshing sleep, and dizziness/fainting, assessed with CDC Short Symptom Screener for myalgic encephalomyelitis/chronic fatigue syndrome) were assessed at baseline and 3 months via electronic surveys sent via text or email. Results Among the first 1000 participants, 722 were COVID+ and 278 were COVID−. Mean age was 41.5 (SD 15.2); 66.3% were female, 13.4% were Black, and 15.3% were Hispanic. At baseline, SARS-CoV-2 symptoms were more common in the COVID+ group than the COVID− group. At 3 months, SARS-CoV-2 symptoms declined in both groups, although were more prevalent in the COVID+ group: upper respiratory symptoms/head/eyes/ears/nose/throat (HEENT; 37.3% vs 20.9%), constitutional (28.8% vs 19.4%), musculoskeletal (19.5% vs 14.7%), pulmonary (17.6% vs 12.2%), cardiovascular (10.0% vs 7.2%), and gastrointestinal (8.7% vs 8.3%); only 50.2% and 73.3% reported no symptoms at all. Symptoms of post-infectious syndromes were similarly prevalent among the COVID+ and COVID− groups at 3 months. Conclusions Approximately half of COVID+ participants, as compared with one-quarter of COVID− participants, had at least 1 SARS-CoV-2 symptom at 3 months, highlighting the need for future work to distinguish long COVID. Clinical Trials Registration NCT04610515. Among persons testing for acute viral symptoms suggestive of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emergent/persistent symptoms at 3 months were common, reported by approximately half of coronavirus disease (COVID)+ participants and one-quarter of COVID− participants. Post-infectious syndromes were equally common in both groups at 3 months, highlighting the challenges in identifying symptoms specific for long COVID and the importance of longitudinal studies including comparison groups.